CARA Therapeutics, Inc. (CARA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151859,
    "name": "CARA Therapeutics, Inc.",
    "stock_name": "CARA Therapeutics, Inc.",
    "full_name": "CARA Therapeutics, Inc.",
    "name_url": "stocks-analysis/cara-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.18",
    "chg": 0.43,
    "chgp": "11.47%",
    "dir": 1,
    "prev_price": "3.75",
    "mcapval": "273.43",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US1407551092",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "71.57 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cara-therapeutics-inc-1151859-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is CARA Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cara-therapeutics-inc-technically-bullish-or-bearish-3547196",
        "imagepath": "",
        "date": "2025-09-20 19:49:18",
        "description": "As of 4 September 2025, the technical trend for CARA Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating strong upward momentum. Daily moving averages also support a bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, which slightly tempers the overall bullish outlook. The Dow Theory and OBV are both mildly bullish on the weekly and monthly timeframes.\n\nIn terms of performance, CARA Therapeutics has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 276.26% compared to the S&P 500's 17.14%. Overall, the current technical stance is bullish, reflecting strong momentum despite some mixed signals in the indicators...."
      },
      {
        "title": "Is CARA Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cara-therapeutics-inc-overvalued-or-undervalued-3543620",
        "imagepath": "",
        "date": "2025-09-20 18:24:10",
        "description": "As of 1 March 2022, CARA Therapeutics, Inc. moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its negative valuation ratios, including a Price to Book Value of -33.03, an EV to EBIT of -9.00, and an EV to EBITDA of -9.05. In comparison to its peers, CARA's EV to EBITDA ratio is significantly worse than Cyteir Therapeutics, Inc. at 0.5746 and NGM Biopharmaceuticals, Inc. at 0.1302, both of which are in a fair or risky valuation category.\n\nDespite its overvaluation, CARA has shown strong recent stock performance, with a year-to-date return of 111.00%, far exceeding the S&P 500's 12.22% over the same period. However, the long-term outlook remains concerning, with a 3-year return of -89.45% compared to the S&P 500's 70.41%...."
      }
    ],
    "total": 7,
    "sid": "1151859",
    "stock_news_url": "https://www.marketsmojo.com/news/cara-therapeutics-inc-1151859"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is CARA Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:49:18

As of 4 September 2025, the technical trend for CARA Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating strong upward momentum. Daily moving averages also support a bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, which slightly tempers the overall bullish outlook. The Dow Theory and OBV are both mildly bullish on the weekly and monthly timeframes. In terms of performance, CARA Therapeutics has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 276.26% compared to the S&P 500's 17.14%. Overall, the current technical stance is bullish, reflecting strong momentum despite some mixed signals in the indicators....

Is CARA Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:24:10

As of 1 March 2022, CARA Therapeutics, Inc. moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its negative valuation ratios, including a Price to Book Value of -33.03, an EV to EBIT of -9.00, and an EV to EBITDA of -9.05. In comparison to its peers, CARA's EV to EBITDA ratio is significantly worse than Cyteir Therapeutics, Inc. at 0.5746 and NGM Biopharmaceuticals, Inc. at 0.1302, both of which are in a fair or risky valuation category. Despite its overvaluation, CARA has shown strong recent stock performance, with a year-to-date return of 111.00%, far exceeding the S&P 500's 12.22% over the same period. However, the long-term outlook remains concerning, with a 3-year return of -89.45% compared to the S&P 500's 70.41%....

View All News